17.74
17.74 (0%)
As of Apr 17, 2025
Pulse Biosciences, Inc. [PLSE]
Source:
Company Overview
Pulse Biosciences, Inc is a novel ablation company committed to health innovation using our patented Nano-pulse Stimulation (“NPS”) technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to nonthermally clear or kill targeted cells. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation (“nsPFA”) technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
| Country | United States |
| Headquarters | hayward, california |
| Phone Number | (510) 906-4600 |
| Industry | manufacturing |
| CEO | Kevin P. Danahy |
| Website | pulsebiosciences.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-56.3 |
| Net Income | $-53.6 |
| Net Cash | $73.7 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -55.9% |
| Profit as % of Stockholder Equity | -46.7% |
Management Effectiveness
| Return on Equity | -46.7% |
| Return on Assets | -40.5% |
| Turnover Ratio | |
| EBITA | $-56.3 |
Balance Sheet and Cash Flow Measures
| Total Assets | $132.5 |
| Total Liabilities | $17.6 |
| Operating Cash Flow | $-36.3 |
| Investing Cash Flow | $-0.1 |
| Financing Cash Flow | $110.1 |
